Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645212 · ClinicalTrials.gov registry record
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
A clinical trial of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, sponsored by Adverum Biotechnologies.
- Active
- Registry status
- 23
- Enrollment target
- 9
- Study locations
NCT04645212: Active study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, sponsored by Adverum Biotechnologies.
NCT04645212 is a study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration that is active but no longer recruiting, run by Adverum Biotechnologies. The registered enrollment target is 23 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04645212, a study of Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Adverum Biotechnologies.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 9
- Study locations
Study Summary
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
Primary Outcome
Severity and incidence of ocular and systemic adverse events
Conditions Studied
Interventions
- BIOLOGICAL ADVM-022
Study Locations (9)
California
- Adverum Clinical Site - Bakersfield
- Adverum Clinical Site - Beverly Hills
Texas
- Adverum Clinical Site - Bellaire
- Adverum Clinical Site - The Woodlands
Colorado
- Adverum Clinical Site - Lakewood
Florida
- Adverum Clinical Site - Deerfield Beach
Nevada
- Adverum Clinical Site - Reno
Pennsylvania
- Adverum Clinical Site - Philadelphia
Tennessee
- Adverum Clinical Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2030-06-26 |
What the registry record for NCT04645212 still lists
NCT04645212 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which ADVM-022 is the first listed.
NCT04645212 lists 9 locations in 7 states (California, Texas, Colorado).
Frequently Asked Questions
What is clinical trial NCT04645212 about?
NCT04645212 is a clinical study titled "Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]". ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
What is the current status of trial NCT04645212?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2020-12-14. Estimated completion is 2030-06-26.
What conditions does trial NCT04645212 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT04645212?
The interventions under investigation include: ADVM-022 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04645212?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04645212 being conducted?
This trial has 9 study locations across California, Colorado, Florida, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04645212's enrollment target sits among peer trials
23 27th of 33 higher than 7 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI